+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028

  • ID: 5312209
  • Report
  • February 2021
  • Region: Global
  • 128 pages
  • Polaris Market Research

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
The global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study. The report “Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 - 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Ankylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual’s spine, starting from lower back sacral bones. AS could also spread to the neck region and damage to other adjoining joints. Ankylosis simply means bone fusion and hard connective tissue and spondylitis means inflammation in the spine and lower part of the vertebrae.

However, there is no cure for ankylosing spondylitis, but medication and proper exercise workouts can ease pain in the spine. Ankylosing spondylitis is started from an individual’s sacroiliac joints, where the spinal cord connects with the pelvic girdle. It impacts the connecting regions of tendons and ligaments attached to the bones and can even fuse an individual’s vertebrae.

Ankylosing spondylitis could cause inflammation and stiffness throughout the body, in few cases spine becomes weak, likely to be fractured easily, also interrupts the functioning of the cauda equine, group of nerves responsible for an individual’s bowel movements, reflexes, and sexual desires, around 40 percent of the patients suffering from AS are likely to suffer from eye-related problem uveitis, eye inflammation causing blurred vision, and individuals with AS in rare cases have large aorta.

Still, researchers are not being able to figure out what triggers ankylosing spondylitis, but there is a strong narrative that people with ankylosing spondylitis have a gene that codes protein called human leukocyte antigen B27 (HLA-B27). HLAs are the proteins, which help an individual’s immune system to differentiate between its cells and foreign particles, though, according to the Spondylitis Association of America, only 2 percent of the people in the market having HLA-B27 gene are expected to develop ankylosing spondylitis in the future. Men are more likely to suffer from ankylosing spondylitis than women, it starts during adulthood, 80 percent of the cases usually begin before 30, and more than 95 percent, by the age of 45.

Rising prevalence of ankylosing spondylitis with faulty lifestyles coupled with patient awareness and new product approvals driving the market forward. According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate was stood at 0.4-14 per 100,000 individuals.

Ankylosing spondylitis prevalence increase to about 5 percent for the individual who is HLA B27 positive. Companies such as AbbVie, Inc., Pfizer, Inc., Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB, Inc., and Merck & Co., Inc. are some of the key players operating in the global ankylosing spondylitis market.

The publisher has segmented the Ankylosing Spondylitis Market report on the basis of drug, treatment type, and region:

Ankylosing Spondylitis, Drug Outlook
  • Cosentyx
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Others
Ankylosing Spondylitis, Treatment Type Outlook

Painkillers and non-steroidal anti-inflammatory drugs (NSAIDs)
Disease-modifying anti-rheumatic drugs (DMARDs)
  • Biological therapies
  • Steroids
  • Physical therapies
  • Surgery
Ankylosing Spondylitis, Regional Outlook
  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • MORE
1. Introduction
1.1. Report Description
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.2. Data Sources

4. Ankylosing Spondylitis Market Insights
4.1. Ankylosing Spondylitis - Industry snapshot
4.2. Ankylosing Spondylitis Market Dynamics
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Ankylosing Spondylitis Market Industry trends

5. Ankylosing Spondylitis Market Assessment by Drug
5.1. Key Findings
5.2. Introduction
5.3. Cosentyx
5.4. Humira
5.5. Simponi
5.6. Remicade
5.7. Enbrel
5.8. Cimzia
5.9. Others

6. Global Ankylosing Spondylitis Market, by Treatment Type
6.1. Key Findings
6.2. Introduction
6.3. Painkillers and non-steroidal anti-inflammatory drugs (NSAIDs)
6.4. Disease-modifying anti-rheumatic drugs (DMARDs)
6.5. Biological therapies
6.6. Steroids
6.7. Physical therapies
6.8. Surgery

7. Ankylosing Spondylitis Market Assessment by Geography
7.1. Key findings
7.2. Introduction
7.3. Ankylosing Spondylitis Market - North America
7.4. Ankylosing Spondylitis Market - Europe
7.5. Ankylosing Spondylitis Market - Asia-Pacific
7.6. Ankylosing Spondylitis Market - Middle East & Africa
7.7. Ankylosing Spondylitis Market - Latin America

8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles
9.1. AbbVie, Inc.
9.2. Amgen, Inc.
9.3. Pfizer, Inc.
9.4. Novartis AG
9.5. Eli Lilly and Company
9.6. UCB, Inc.
9.7. Johnson & Johnson Services, Inc.
9.8. Merck & Co., Inc.
9.9. Boehringer Ingelheim International GmbH

List of Tables
Table 1 Global Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 2 Global Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 3 Ankylosing Spondylitis Market Assessment, By Geography, 2016 - 2028 (USD Million)
Table 4 North America: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 5 North America: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 6 U.S.: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 7 U.S.: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 8 Canada: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 9 Canada: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 10 Europe: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 11 Europe: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 12 UK: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 13 UK: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 14 France: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 15 France: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 16 Germany: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 17 Germany: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 18 Italy: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 19 Italy: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 20 Hungary: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 21 Hungary: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 22 Croatia: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 23 Croatia: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 24 Austria: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 25 Austria: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 26 Asia Pacific: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 27 Asia Pacific: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 28 China: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 29 China: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 30 India: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 31 India: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 32 Malaysia: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 33 Malaysia: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 34 Japan: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 35 Japan: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 36 Indonesia: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 37 Indonesia: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 38 Australia: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 39 Australia: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 40 Middle East & Africa: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 41 Middle East & Africa: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 42 Saudi Arabia: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 43 Saudi Arabia: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 44 UAE: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 45 UAE: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 46 Israel: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 47 Israel: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 48 South Africa: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 49 South Africa: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 50 Latin America: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 51 Latin America: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 52 Mexico: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 53 Mexico: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 54 Brazil: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 55 Brazil: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)
Table 56 Argentina: Ankylosing Spondylitis Market, By Drug , 2016 - 2028 (USD Million)
Table 57 Argentina: Ankylosing Spondylitis Market, By Treatment Type, 2016 - 2028 (USD Million)

List of Figures
Figure 1 Market Highlights (2020, Revenue)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top Down & Bottom Up Approach
Figure 4 Market by Geography
Figure 5 Porter’s Five Forces
Figure 6 Market by Drug
Figure 7 Global Ankylosing Spondylitis Market, By Drug , 2020 & 2028 (USD Million)
Figure 8 Market by Treatment Type
Figure 9 Global Ankylosing Spondylitis Market, By Treatment Type, 2020 & 2028 (USD Million)
Figure 10 Ankylosing Spondylitis Market Assessment, By Geography, 2016 - 2028 (USD Million)
Figure 11 Strategic Analysis - Ankylosing Spondylitis Market
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • Johnson & Johnson Services Inc.
  • Eli Lilly and Company
  • UCB Inc.
  • Merck & Co. Inc.
Note: Product cover images may vary from those shown
Adroll
adroll